Company
ArsenalBio
Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.
Also known as Arsenal Biosciences, Inc
- Business model
- B2B
- Legal name
- Arsenal Biosciences, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
ArsenalBio develops programmable cell therapies using genetic circuits to enhance CAR-T therapies for solid tumors. By controlling specificity, on-tumor activation, potency, and durability, the company leverages CRISPR, AI, and data analytics to reprogram T cells and identify new drug candidates for improved cancer treatment.
Funding snapshot
- Total raised
- $579MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $325M2024-07-09
Funding rounds
- Round, 2024
- $325M2024-07-09, SEC form D sold, 26 investors
- Round, 2022
- $221M2022-02-10, SEC form D sold, 17 investors
- Round, 2020
- $33M2020-12-14, SEC form D sold, 9 investors
Loading relationship preview